Perfil clínico e epidemiológico dos pacientes portadores de doenças intersticiais pulmonares em um Centro De Especialidades Médicas em Belém-PA

Abstract

Objective: To characterize the epidemiological profile associated with the clinical repercussions of patients diagnosed with interstitial pulmonary disease who are being accompanied by the Center of Medical Specialties of the Centro Universitário do Estado do Pará (CEMEC-CESUPA) in Belém do Pará, to thru it contribute as a source for other papers. Methodology: The study developed is cross-sectional, descriptive and observational with quantitative and qualitative, descriptive and analytical approach, with data collection in the medical records of patients older than 18 years treated at the Center of Medical Specialties of the Centro Universitário do Estado do Pará (CEMEC-CESUPA) conducted from January 2018 to June 2022. Results: 74 patients were included. The majority (51 or 68.9%) were female and 23 (31.1%) were male. More than half (42 or 56.8%) were aged 60 years or older. 36.5% of the individuals had final diagnosis of idiopathic pulmonary fibrosis, 22 (29.7%) had hypersensitivity pneumopathy, 10 (13.5%) had pneumopathy secondary to rheumatoid arthritis. Regarding the exposure of patients with IPD, it was identified that 15 individuals (20.3%) had exposure to birds and 11 (14.9%) had exposure to mold. As for the symptoms presented, most (68 or 91.9%) had dyspnea, (57 or 77%) had a cough, and 45 or 60.8% had Velcro crackles. Among the tomographic alterations, most (58 or 78.4%) had ground glass, (57 or 77.0%) had septal thickening, (45 or 60.8%) bronchiectasis and (43 or 58.1%) had fibrosis. Regarding the main drugs used in the treatment of patients diagnosed with IPD, it was found that prednisone corresponds to 55.4%, nintedanib 21.6%, acetylcysteine 14.9% and azathioprine 13.5%. Conclusion: This study contributed with important clinical and epidemiological information for the creation of a clinical profile of patients, in addition to expanding the knowledge about their tomographic changes and the main therapies used in the treatment of interstitial lung diseases.